Advancements in the Treatment and Management of SCLC: Updates From ASCO 2025

Panelists discussed evolving strategies in limited-stage and extensive-stage small cell lung cancer (LS-SCLC and ES-SCLC), including the integration of consolidation durvalumab in LS-SCLC, emerging first-line chemoimmunotherapy regimens in ES-SCLC, maintenance strategies such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305), and the promising future role of novel agents like T-cell engagers, antibody-drug conjugates, and B7-H3–targeted therapies (including DeLLphi-304) in reshaping the treatment landscape.

EP. 1: Panel Insights: Interpreting ADRIATIC Outcomes and Tailoring LS-SCLC Treatment

June 23rd 2025

Panelists agreed the ADRIATIC trial is practice-changing for limited-stage small cell lung cancer, establishing durvalumab as the new standard post chemoradiation due to its significant survival benefit and manageable toxicity, while also highlighting the need for multidisciplinary coordination and raising questions about agent selection and evolving radiation strategies.

EP. 2: Multidisciplinary Approaches to Managing LS-SCLC: Immunotherapy, Paraneoplastic Syndromes, and Post-CCRT Care

June 23rd 2025

Panelists emphasized that while timely initiation of durvalumab post chemoradiation is ideal in LS-SCLC, consistent with ADRIATIC trial protocols, patient recovery and multidisciplinary input—especially in cases involving treatment-related toxicity or neurologic comorbidities—are essential to guide safe, individualized decision-making.

EP. 3: Navigating Disease Progression During and After Durvalumab: Expert Insights

June 30th 2025

Panelists discussed the importance of close monitoring during consolidation durvalumab in LS-SCLC—especially for pneumonitis risk—and noted that relapse management is shifting away from routine platinum rechallenge toward more personalized use of newer agents like lurbinectedin and tarlatamab, based on timing, tolerability, and individual patient factors.

EP. 4: ADRIATIC Trial: Key Insights Into Progression Patterns and Their Impact on Treatment Decisions

June 30th 2025

Panelists highlighted the ADRIATIC trial’s survival benefits with durvalumab in LS-SCLC while discussing exploratory data that identified immune microenvironment features distinguishing long-term responders from early progressors, emphasizing the need for validated biomarkers to personalize immunotherapy and improve outcomes beyond current standards.

EP. 5: ES-SCLC Treatment Decisions: Expert Insights into Clinical Trial Data and Real-World Evidence

July 7th 2025

Panelists reviewed first-line treatment for extensive-stage SCLC, emphasizing platinum-based chemotherapy plus a PD-L1 inhibitor—typically carboplatin with either atezolizumab or durvalumab—with 4 cycles standard, noting both agents offer survival benefits and are largely interchangeable, while highlighting emerging therapies and ongoing trials that may soon refine and personalize this evolving treatment landscape.

EP. 6: ES-SCLC Treatment Decisions: Use of Radiotherapy for Consolidation

July 7th 2025

Panelists discussed the nuanced management of brain metastases in small cell lung cancer, highlighting the preference for systemic therapy first in asymptomatic cases to avoid upfront radiation adverse effects, the selective use of stereotactic radiosurgery for symptomatic lesions, and the cautious, individualized approach to thoracic consolidation radiation amid concerns about toxicity and mixed data, emphasizing the critical role of multidisciplinary collaboration and ongoing research to optimize treatment strategies.

EP. 7: Optimizing Maintenance Therapy in ES-SCLC: Expert Approaches and Key Decision Factors

July 14th 2025

Panelists highlighted the M40 trial’s promising results showing that adding chemotherapy to atezolizumab maintenance after initial chemo-immunotherapy significantly improves overall survival in extensive-stage disease, offering a new strategy to reduce relapse risk during the vulnerable post-induction period with manageable toxicity, and marking a potential shift in the treatment paradigm for extending long-term patient outcomes.

EP. 8: ASCO 2025: Expert Insights on IMforte Trial Findings and Lurbinectedin in First-Line ES-SCLC Maintenance

July 14th 2025

Panelists emphasized that while the addition of the new drug to maintenance therapy marks a major advance with improved survival, it also brings increased toxicity that necessitates careful patient selection and shared decision-making—especially considering real-world tolerability, impacts on quality of life, subsequent treatment sequencing, and the unresolved questions around its use in patients with brain metastases, underscoring the need for biomarkers and individualized care in this evolving treatment landscape.

EP. 9: Tarlatamab in Relapsed SCLC: An Expert Discusses DeLLphi Trial Insights

July 21st 2025

Panelists highlighted a pivotal phase 3 trial demonstrating that a novel targeted therapy significantly improves overall survival and offers durable responses in second-line small cell lung cancer, positioning it as a preferred option after frontline chemoimmunotherapy despite logistical challenges and the need for multidisciplinary coordination, with careful patient selection and ongoing clinical trials essential to optimizing sequencing and expanding treatment options.

EP. 10: Lurbinectedin in Relapsed ES-SCLC: Response, Real-World Data, and Clinical Implications

July 21st 2025

Panelists discussed real-world data confirming that a novel targeted agent for extensive-stage small cell lung cancer offers consistent efficacy and durable responses across multiple lines of therapy, with a favorable toxicity profile enhancing quality of life; treatment selection is individualized based on patient factors and logistical considerations, while vigilant brain metastasis surveillance and multidisciplinary coordination remain essential to optimize outcomes.

EP. 11: Patient Conversations and Considerations in the Extensive-Stage Relapse Setting

July 28th 2025

Panelists emphasized that clear, compassionate, and ongoing communication with patients diagnosed with small cell lung cancer is vital to support informed decision-making amid evolving treatment options, highlighting the importance of maintaining a broad therapeutic arsenal, integrating multidisciplinary and palliative care early, and regularly reassessing goals to optimize quality of life and treatment outcomes throughout the often prolonged disease course.

EP. 12: Exploring the Future of SCLC: Insights Anticipated From the SWOG S2409 (PRISM) Trial

July 28th 2025

Panelists highlighted a forthcoming large cooperative-group trial in small cell lung cancer that pioneers precision medicine by using molecular subtyping to guide biomarker-driven therapy combined with immunotherapy, aiming to personalize treatment across diverse patient populations and generate extensive molecular and clinical data to advance understanding and improve outcomes in this historically challenging disease.

EP. 13: Insights on Resistance Mechanisms and Sequencing Strategies for DLL3-Targeted and ADC Therapies in ES-SCLC

August 4th 2025

Panelists discussed advances in overcoming resistance in extensive-stage small cell lung cancer, highlighting promising antibody-drug conjugates and immune-based therapies targeting DLL3 and B7-H3, including bispecific T-cell engagers and CAR T cells, while emphasizing the critical need for biomarkers to guide therapy selection and optimize combinations to improve durability, intracranial activity, and patient outcomes amid the challenges of relapse and immune evasion.

EP. 14: Emerging ADCs in SCLC: Spotlight on B7-H3 and MHB088C

August 4th 2025

Panelists discussed the challenges of biomarkers in SCLC, emphasizing that targets like DLL3 and B7-H3 show promise but require dynamic monitoring, and highlighted ongoing trials exploring antibody-drug conjugates and targeted therapies to potentially complement or replace platinum chemotherapy in personalized treatment approaches.

EP. 15: Final Thoughts and Future Perspectives in SCLC

August 4th 2025

Panelists discussed the evolving small cell lung cancer treatment landscape, emphasizing the need to improve clinical trial accessibility, advance biomarker research, and better manage brain metastases, while highlighting promising therapies like checkpoint inhibitors and antibody-drug conjugates that offer hope for durable responses amid ongoing challenges.

x